Big biotech, Big pharma, Biotech, Partnering, Pharma

Sobi and Biogen Idec sign a pharma deal for hemophilia

Posted on 22 September 2014

Tags: , , ,

Swedish Orphan Biovitrum has elected to add the preclinical rFVIIIFc-XTEN-vWF fusion molecule to the company's pharma deal with Biogen Idec.

Under the terms of Sobi and Biogen Idec's agreement, Sobi has the right to elect to include the rFVIIIFc-XTEN-vWF fusion molecule in the collaboration.

Sobi is required to make a payment to Biogen Idec to include this program in the collaboration agreement.

Biogen Idec and Sobi are collaborators in the development and commercialisation of Eloctate(TM) and Alprolix(TM) for haemophilia A and B.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Biogen Idec

Report: Partnering Deals and Alliances with Big Pharma  

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply